Gemphire Therapeutics Inc (NASDAQ:GEMP)‘s stock had its “outperform” rating reissued by equities researchers at RBC Capital Markets in a report issued on Friday. They currently have a $25.00 target price on the stock. RBC Capital Markets’ target price would indicate a potential upside of 145.34% from the company’s previous close.
GEMP has been the subject of several other research reports. Jefferies Group started coverage on shares of Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity started coverage on shares of Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued a “buy” rating and a $17.00 price objective for the company. Laidlaw started coverage on shares of Gemphire Therapeutics in a research report on Tuesday, September 6th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Royal Bank Of Canada started coverage on shares of Gemphire Therapeutics in a research report on Tuesday, August 30th. They issued an “outperform” rating and a $25.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $20.40.
Shares of Gemphire Therapeutics (NASDAQ:GEMP) traded up 4.61% during trading on Friday, hitting $10.66. The stock had a trading volume of 14,502 shares. The stock’s market capitalization is $38.65 million. Gemphire Therapeutics has a 52 week low of $8.80 and a 52 week high of $13.98. The stock’s 50 day moving average is $10.85 and its 200 day moving average is $10.85.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/rbc-capital-markets-reaffirms-outperform-rating-for-gemphire-therapeutics-inc-gemp.html
In other Gemphire Therapeutics news, insider David Lowenschuss bought 11,120 shares of the company’s stock in a transaction on Wednesday, August 10th. The stock was bought at an average price of $10.00 per share, for a total transaction of $111,200.00. Following the transaction, the insider now owns 806,247 shares of the company’s stock, valued at approximately $8,062,470. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jeffrey S. Mathiesen bought 4,000 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were acquired at an average price of $10.00 per share, with a total value of $40,000.00. Following the transaction, the chief financial officer now directly owns 3,927 shares in the company, valued at approximately $39,270. The disclosure for this purchase can be found here.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of dyslipidemia. It is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.